← All trials
NCT03184766
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 10, 2016
- Primary completion
- Jan 30, 2017
- Completion date
- Jan 30, 2017
- First posted
- —
- Last posted
- —
- Enrollment
- 55
- Arms / groups
- 6 / —
- Source
- AACT · pre-existing
Sponsors
- Reckitt Benckiser PharmaceuticalLead sponsor
- Simbec-OrionCollaborator
- Simbec-OrionOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.